US5730713A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Removal of selected factors from whole blood or its components
Assignee: Aventis Pharmaceuticals Inc
•
Filing: 1996-06-03
•
Granted: 1998-03-24
•
Expires: 2016-06-03
Abstract
Abstract This invention provides a composition, device and method for the removal of selected factors, such as cytokines or pharmaceuticals, from a substance such as whole blood or plasma. Advantageously, the invention provides for the treatment or prevention of septic shock syndrome or other conditions evidenced by the presence of cytokines in a patient by contacting the patient's whole blood with a composition comprising silica and a surface treatment material, such as heparin, but preferably human serum albumin (HSA). The treatment lowers the cytokine concentration of the blood. Pharmaceuticals can be removed from an individual's whole blood or plasma, such as for use in treating drug overdosage.
Inventors
- 👤 Thomas B. Okarma
- 👤 John Blankenship
- 👤 Abraham T. Lin
- 👤 Mohammad A. Elkalay
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 00:37
CPC Classifications
A; A61; A61M; A61M1/00; A61M1/36; A61M1/3679; A61M1/34; A61M1/342; A61M1/3424; A61M1/3431; A61M1/3621; A61M1/3643; A61M1/3644; A61M1/3672; A61M1/3673; Y; Y10; Y10S; Y10S530/00; Y10S530/81; Y10S530/811
Claims Analysis
Total Claims: 45
Claim 1
Independent Claim
87 words
A method for removing selected factors in a mammalian subject's blood or blood component, comprising contacting the blood or blood component with a composition of matter comprising pretreated amorphous, particulate, granular silica and silica pretreating agent selected from the group consisting of heparin and albumin, wherein the silica has a specific surface area of at least 150 m 2 /g, and contains between 0.5 cc/g and 2.5 cc/g of porosity, whereby at least a portion of the selected factors are removed from the blood or blood component.
Claim 2
Independent Claim
87 words
A method for removing selected factors in a mammalian subject's blood or blood component, comprising contacting the blood or blood component with a composition of matter comprising pretreated amorphous, particulate, granular silica and silica pretreating agent selected from the group consisting of heparin and albumin, wherein the silica has a specific surface area of at least 150 m 2 /g, and contains between 0.5 cc/g and 2.5 cc/g of porosity, whereby at least a portion of the selected factors are removed from the blood or blood component.
Claim 3
Dependent Claim
24 words
The method of claim 1, wherein the specific surface area of the silica is between 150 μm 2 /g and 1000 m 2 /g.
Claim 4
Dependent Claim
24 words
The method of claim 2, wherein the specific surface area of the silica is between 200 μm 2 /g and 600 m 2 /g.
Claim 5
Dependent Claim
18 words
The method of claim 1 wherein the porosity of the silica is between 0.8 cc/g and 1.5 cc/g.
Claim 6
Dependent Claim
12 words
The method of claim 1 wherein the silica is substantially chemically unmodified.
Claim 7
Dependent Claim
19 words
The method of claim 1 in which the silica particles have a mean diameter less than about 1 mm.
Claim 8
Dependent Claim
20 words
The method of claim 6 in which the silica particles have a mean diameter between about 50 and 250 microns.
Claim 9
Dependent Claim
21 words
The method of claim 1 in which the silica has a mean pore diameter of about 30 Å to 300 Å.
Claim 10
Dependent Claim
21 words
The method of claim 8 in which the silica has a mean pore diameter of about 60 Å to 200 Å.
Claim 11
Dependent Claim
21 words
The method of claim 1 comprising albumin in an amount between 1% and 25% by weight of the silica pretreating agent.
Claim 12
Dependent Claim
19 words
The method of claim 10 comprising albumin in an amount between 2.5% and 5% of the silica pretreating agent.
Claim 13
Dependent Claim
20 words
The method of claim 1 in which the silica pretreating agent is substantially devoid of covalent attachment to the silica.
Claim 14
Dependent Claim
26 words
The method of claim 1 in which the selected factors comprise cytokines, complement molecules, serotonin, histamine, cholesterol molecules, a myoglobin component, angiogenesis factor or a pharmaceutical.
Claim 15
Dependent Claim
18 words
The method of claim 1 further comprising a step of subjecting the subject's blood to an anticoagulation regimen.
Claim 16
Dependent Claim
13 words
The method of claim 14 wherein the anticoagulation regimen comprises use of citrate.
Claim 17
Dependent Claim
15 words
The method of claim 14 wherein the anticoagulation regimen comprises use of citrate and heparin.
Claim 18
Independent Claim
87 words
A method for treating a condition characterized by the presence of selected factors in a mammalian subject's blood or blood component, comprising contacting the blood or blood component with a composition of matter comprising pretreated amorphous, particulate, granular silica and silica pretreating agent selected from the group consisting of heparin and albumin, wherein the silica has a specific surface area of at least 150 m 2 /g, contains between 0.5 cc/g and 2.5 cc/g of porosity and introducing the contacted blood or blood component to the subject.
Claim 19
Independent Claim
87 words
A method for treating a condition characterized by the presence of selected factors in a mammalian subject's blood or blood component, comprising contacting the blood or blood component with a composition of matter comprising pretreated amorphous, particulate, granular silica and silica pretreating agent selected from the group consisting of heparin and albumin, wherein the silica has a specific surface area of at least 150 m 2 /g, contains between 0.5 cc/g and 2.5 cc/g of porosity and introducing the contacted blood or blood component to the subject.
Claim 20
Dependent Claim
12 words
The method of claim 17 wherein the condition is septic shock syndrome.
Claim 21
Dependent Claim
12 words
The method of claim 17 wherein the condition is capillary leak syndrome.
Claim 22
Dependent Claim
12 words
The method of claim 17 wherein the condition is acute renal failure.
Claim 23
Dependent Claim
11 words
The method of claim 17 wherein the condition is pharmaceutical overdose.
Claim 24
Dependent Claim
30 words
The method of claim 17 wherein the selected factors comprise serotonin, histamine, complement molecules, cytokines, interferon, tumor necrosis factor (TNF), cholesterol molecules, anglogenesis factor, a myoglobin component, or a pharmaceutical.
Claim 25
Dependent Claim
63 words
A composition of matter capable of removing selected factors from blood or a blood component, composition of matter comprising pretreatment amorphous, particulate, granular silica and silica pretreating agent, wherein the silica has a specific surface area of at least 150 m 2 /g, and contains between 0.5 cc/g and 2.5 cc/g of porosity, and wherein the silica pretreating agent is heparin or albumin.
Claim 26
Dependent Claim
63 words
A composition of matter capable of removing selected factors from blood or a blood component, composition of matter comprising pretreatment amorphous, particulate, granular silica and silica pretreating agent, wherein the silica has a specific surface area of at least 150 m 2 /g, and contains between 0.5 cc/g and 2.5 cc/g of porosity, and wherein the silica pretreating agent is heparin or albumin.
Claim 27
Dependent Claim
24 words
The composition of claim 23 wherein the specific surface area of the silica is between 150 μm 2 /g and 1000 m 2 /g.
Claim 28
Dependent Claim
24 words
The composition of claim 24, wherein the specific surface area of the silica is between 200 m 2 /g and 600 m 2 /g.
Claim 29
Dependent Claim
18 words
The composition of claim 23 wherein the porosity of the silica is between 0.8 cc/g and 1.5 cc/g.
Claim 30
Dependent Claim
12 words
The composition of claim 23 wherein the silica is substantially unmodified chemically.
Claim 31
Dependent Claim
19 words
The composition of claim 23 in which the silica particles have a mean diameter less than about 1 mm.
Claim 32
Dependent Claim
20 words
The composition of claim 28 in which the silica particles have a mean diameter between about 50 and 250 microns.
Claim 33
Dependent Claim
21 words
The composition of claim 23 in which the silica has a mean pore diameter of about 30 Å to 300 Å.
Claim 34
Dependent Claim
21 words
The composition of claim 30 in which the silica has a mean pore diameter of about 60 Å to 200 Å.
Claim 35
Dependent Claim
21 words
The composition of claim 23 comprising albumin in an amount between 1% and 25% by weight of the silica pretreating agent.
Claim 36
Dependent Claim
21 words
The composition of claim 32 comprising albumin in an amount between 2.5% and 5% by weight of the silica pretreating agent.
Claim 37
Dependent Claim
20 words
The composition of claim 23 in which the silica pretreating agent is substantially devoid of covalent attachment to the silica.
Claim 38
Dependent Claim
21 words
The composition of claim 23 in which the selected factors comprise cytokines, complement molecules, serotonin, histamine, cholesterol molecules, or angiogenesis factor.
Claim 39
Dependent Claim
15 words
The composition of claim 23, wherein the composition is immobilized within a porous solid matrix.
Claim 40
Dependent Claim
9 words
A medical device containing the composition of claim 23.
Claim 41
Dependent Claim
15 words
A composition of matter according to claim 23, wherein the silica is substantially unmodified chemically.
Claim 42
Dependent Claim
11 words
The method of claim 1, wherein said blood component is plasma.
Claim 43
Dependent Claim
11 words
The method of claim 17, wherein said blood component is plasma.
Claim 44
Dependent Claim
14 words
A composition of matter according to claim 23, wherein the blood component is plasma.
Claim 45
Dependent Claim
14 words
A composition of matter according to claim 38, wherein the blood component is plasma.
References Cited (Backward Citations)
US3522346A
Cited
US3607857A
Cited
US4059685A
Cited
US4006059A
Cited
US3998946A
Cited
US4102746A
Cited
GB1536425A
Cited
US4072566A
Cited
DE3109123A1
Cited
US4787974A
Cited
US4420395A
Cited
US4472303A
Cited
US4728432A
Cited
JPS6158664A
Cited
US4748121A
Cited
EP0219053A2
Cited
US4883765A
Cited
US4861707A
Cited
US5294401A
Cited
WO1988009202A1
Cited
US4865841A
Cited
US5041079A
Cited
US4963265A
Cited
US5022988A
Cited
WO1990000903A1
Cited
JPH06158664A
Cited
US5437861A
Cited
US5523096A
Cited
US5421815A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-03-23 | 2001-09-22 | 2002-03-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-03-23 | 2005-09-22 | 2006-03-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-03-23 | 2009-09-22 | 2010-03-24 | $7700.00 | Window Closed / Lapsed |